Clinical meaning
Cold agglutinin disease (CAD) is a form of autoimmune hemolytic anemia (AIHA) caused by IgM autoantibodies (cold agglutinins) that bind to red blood cell surface antigens at temperatures below core body temperature (optimally at 0-4C but pathogenic antibodies with high thermal amplitude can bind at temperatures approaching 37C). These IgM cold agglutinins are primarily directed against the I/i antigen system on the RBC surface -- the I antigen is expressed on adult RBCs while the i antigen predominates on fetal and neonatal RBCs. CAD accounts for approximately 15-25% of all AIHA cases and has a median age of onset of 65-70 years. The disease exists in two forms: primary (idiopathic) CAD, which is now recognized as a clonal lymphoproliferative disorder of B lymphocytes (classified by WHO as a distinct entity related to but separate from lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia), and secondary cold agglutinin syndrome, which occurs in association with lymphoproliferative disorders (CLL, lymphoma, Waldenstrom) or infections (Mycoplasma pneumoniae, Epstein-Barr virus/infectious mononucleosis -- typically transient and self-limited). The pathogenesis involves complement-mediated hemolysis rather than the antibody-dependent cellular cytotoxicity that characterizes warm AIHA. When IgM cold agglutinins bind to RBC surface antigens in the cooler peripheral circulation (fingers, toes, ears, nose where blood temperature drops to 28-31C), the pentameric IgM molecule is an extremely efficient complement activator -- a single IgM molecule bound to the RBC surface can initiate the classical complement pathway by binding C1q. The complement cascade proceeds through C1, C4, C2, and C3, depositing C3b on the RBC surface. When the RBCs return to the warmer central circulation (37C), the IgM antibody dissociates from the RBC surface (its binding is temperature-dependent), but the covalently bound C3b remains. In most cases, the complement cascade does NOT proceed to completion (C5-C9 membrane attack complex formation and intravascular hemolysis) because of protective complement regulatory proteins (CD55/decay-accelerating factor, CD59/membrane inhibitor of reactive lysis) on the RBC surface. Instead, C3b is cleaved to iC3b and then C3d by factor I and its cofactors. RBCs coated with C3b and iC3b are recognized and phagocytosed by macrophages in the liver and spleen (which express complement receptors CR1 and CR3), producing extravascular hemolysis. This complement-mediated extravascular hemolysis is the predominant mechanism of RBC destruction in CAD. However, in some patients -- particularly during acute exacerbations triggered by cold exposure, infections, or surgery -- complement activation may proceed fully through the terminal pathway to MAC formation, causing intravascular hemolysis with hemoglobinemia, hemoglobinuria, and potentially acute kidney injury. The clinical manifestations of CAD include chronic hemolytic anemia (typically mild to moderate with hemoglobin 8-12 g/dL, though acute exacerbations can be severe), acrocyanosis (bluish discoloration of the fingers, toes, ears, and nose caused by RBC agglutination in the cool peripheral microcirculation -- this is distinct from Raynaud phenomenon and does not involve vasospasm), jaundice (from bilirubin production during hemolysis), fatigue, cold intolerance, and dark urine during hemolytic exacerbations. The direct antiglobulin test (DAT/Coombs test) is positive for complement (C3d) but NEGATIVE for IgG -- this complement-only positive DAT pattern is the serological hallmark that distinguishes cold AIHA from warm AIHA (which shows IgG-positive DAT). Cold agglutinin titers are elevated (typically >1:64 at 4C; high titers >1:512 are more clinically significant). The thermal amplitude (the highest temperature at which the antibody binds to RBCs) is a critical determinant of clinical severity -- antibodies with high thermal amplitude (binding at 30-37C) cause more severe disease because they can agglutinate RBCs even in the relatively warm central circulation. Treatment of CAD differs fundamentally from warm AIHA because corticosteroids and splenectomy (the mainstays of warm AIHA treatment) are largely INEFFECTIVE in CAD. The ineffectiveness of splenectomy reflects the fact that complement-mediated RBC clearance occurs predominantly in the LIVER (by hepatic Kupffer cells expressing complement receptors), not the spleen. The ineffectiveness of corticosteroids reflects the complement-mediated (rather than antibody-mediated) mechanism of hemolysis. Current first-line therapy for CAD requiring treatment is rituximab (anti-CD20 monoclonal antibody) either alone or in combination with bendamustine, which targets the clonal B-cell population producing the pathogenic IgM cold agglutinins. Sutimlimab (Enjaymo), a humanized anti-C1s monoclonal antibody that inhibits the classical complement pathway, was FDA-approved in 2022 specifically for CAD -- it is the first complement-targeted therapy approved for this disease and provides rapid improvement in hemoglobin by blocking complement-mediated hemolysis. Cold avoidance is a critical non-pharmacological intervention -- patients must protect extremities from cold, use warm IV fluids, and maintain a warm environment during hospitalization. RBC transfusion, when needed, requires careful blood bank coordination because cold agglutinins can interfere with crossmatching and cause agglutination of transfused RBCs; blood must be administered through an in-line blood warmer to prevent agglutination in the IV tubing.